| Code | 9825C | ||||||||||
| MA number | 44/0393/18-S | ||||||||||
| Product Form: | tbl flm 60x50 mg (fľ.HDPE) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Sandoz Pharmaceuticals d.d., Slovenia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 12.12.2018 |
| SPC: |
SPC_Dasatinib Sandoz 50 mg_09.2023.pdf
|
| PIL: |
PIL_Dasatinib Sandoz 50 mg_09.2023.pdf
|
| Safety feature | Yes |
| Data update: | 06.09.2023 |
